文献速递前列腺癌

细胞外囊泡在前列腺癌耐药中的诊断与预后意义:文献系统综述

Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: A systematic review of the literature.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-03-09

本系统综述按PRISMA指南检索PubMed、EMBASE和Google Scholar,纳入33项研究,评估细胞外囊泡(EV)作为耐药前列腺癌诊断与预后生物标志物的价值。系统综述的EV标志物中,61%为预后相关分子,18%为诊断相关分子,21%兼具两种意义;蛋白质、mRNA和miRNA是研究最多的分子类型。作者指出,目前所有入选的EV标志物均未超出临床前研究阶段,其可转化性距临床应用尚远。

要点

  • 系统综述纳入33项研究,评估EV标志物在耐药前列腺癌中的诊断与预后价值。
  • 系统综述的EV标志物中,61%为预后相关,18%为诊断相关,21%兼具两种意义。
  • 蛋白质、mRNA和miRNA是研究最多、被提议用于预测晚期前列腺癌治疗耐药或敏感的分子。

核心结论

  • 本分析提供了EV作为耐药前列腺癌潜在临床生物标志物的当前全景。
  • 尽管付出诸多努力,EV生物标志物在前列腺癌中的应用目前仍处于早期阶段:所有入选的EV标志物均未超出临床前研究,其可转化性距临床环境尚远。

研究设计与样本

  • 本系统综述按照PRISMA指南进行,全面检索PubMed、EMBASE和Google Scholar数据库以完成文献检索。
  • 共纳入并调查33项研究。

主要发现

  • 在所有系统综述的EV标志物中,主要为具有预后意义的分子(61%)、具有诊断相关性的分子(18%)以及兼具两种用途的分子(21%)。
  • 在所有从EV中分离分析的分子中,蛋白质、mRNA和miRNA是研究最多且被提议作为诊断或预测晚期前列腺癌治疗耐药/敏感性的潜在工具的分子。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有入选的EV标志物均未超出临床前研究,其可转化性距临床环境尚远。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical behavior of prostate cancer is highly heterogeneous, with most patients diagnosed with localized disease that successfully responds to surgery or radiotherapy. However, a fraction of men relapse after initial treatment because they develop drug resistance. The failure of anticancer drugs leaves resistant cancer cells to survive and proliferate, negatively affecting patient survival. Thus, drug resistance remains a significant obstacle to the effective treatment of prostate cancer patients. In this scenario, the involvement of extracellular vesicles (EVs) in intrinsic and acquired resistance have been reported in several tumors, and accumulating data suggests that their differential content can be used as diagnostic or prognostic factors. Thus, we propose a systematic study of literature to provide a snapshot of the current scenario regarding EVs as diagnostic and prognostic biomarkers resource in resistant prostate cancer. METHODS: We performed the current systematic review according to PRISMA guidelines and comprehensively explored PubMed, EMBASE and Google Scholar databases to achieve the article search. RESULTS: Thirty-three studies were included and investigated. Among all systematically reviewed EV biomarkers, we found mainly molecules with prognostic significance (61%), molecules with diagnostic relevance (18%), and molecules that serve both purposes (21%). Moreover, among all analyzed molecules isolated from EVs, proteins, mRNAs, and miRNAs emerged to be the most investigated and proposed as potential tools to diagnose or predict resistance/sensitivity to advanced PCa treatments. DISCUSSION: Our analysis provides a snapshot of the current scenario regarding EVs as potential clinical biomarkers in resistant PCa. Nevertheless, despite many efforts, the use of EV biomarkers in PCa is currently at an early stage: none of the selected EV biomarkers goes beyond preclinical studies, and their translatability is yet far from clinical settings.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Grimaldi AM, Salvatore M, Cavaliere C, et al. Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: A systematic review of the literature. Prostate Cancer Prostatic Dis. 2022. PMID: 35264776. doi:10.1038/s41391-022-00521-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。